期刊
HYPERTENSION IN PREGNANCY
卷 30, 期 2, 页码 194-202出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/10641950903242675
关键词
Plasminogen activator inhibitor-2; First-trimester screening; Preeclampsia; Uterine artery Doppler
资金
- Fetal Medicine Foundation (UK Charity) [1037116]
- PerkinElmer, Inc., Wallac Oy, Turku, Finland
Objective. In patients with preeclampsia maternal plasma concentration of plasminogen activator inhibitor-2 (PAI-2) is reduced. The objective of the study was to determine if the altered levels of PAI-2 precede the onset of the disease. Methods. Plasma PAI-2 was measured at 11-13 weeks of gestation in 119 pregnancies that developed preeclampsia, 85 that developed gestational hypertension and 204 controls. Results. There were no significant differences in PAI-2 between the preeclampsia, gestational hypertension and controls (1.07 MoM, 1.08 MoM and 0.96 MoM). Conclusion. The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据